Related Experiment Video
Updated: May 12, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Combination therapy in hypertension
Manuel Gorostidi1, Alejandro de la Sierra
1Department of Nephrology, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain.
Advances in Therapy
|April 5, 2013
Summary
Effective hypertension management requires combination therapy for most patients. Strategies include early combination treatment and single-pill fixed-dose combinations to improve blood pressure control.
Area of Science:
- Cardiology
- Nephrology
- Public Health
Background:
- Hypertension is a leading global cause of mortality and a major risk factor for cardiovascular and renal diseases.
- Despite proven benefits, blood pressure control rates remain poor worldwide, even in high-income nations.
- Approximately 75% of patients require more than monotherapy for adequate blood pressure control.
Purpose of the Study:
- To review current strategies for improving blood pressure control in hypertensive patients.
- To highlight the importance of combination therapy in achieving treatment goals.
Main Methods:
- Review of current clinical guidelines and treatment strategies for hypertension management.
- Analysis of the role of monotherapy versus combination therapy in achieving blood pressure control.
Main Results:
- Monotherapy is insufficient for the majority of hypertensive patients.
- Combination therapy, including initial two-drug regimens and fixed-dose combinations, is crucial for effective blood pressure management.
- Preferred combinations involve renin-angiotensin blockers with calcium channel blockers or diuretics.
Conclusions:
- Improving blood pressure control necessitates a shift towards earlier and more effective combination therapies.
- Fixed-dose combination pills offer a practical approach to enhance patient adherence and treatment efficacy.
- Some patients may require triple combination therapy to reach target blood pressure levels.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...